254 related articles for article (PubMed ID: 28247415)
1. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C
Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415
[TBL] [Abstract][Full Text] [Related]
2. Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
Novakova Z; Belousova N; Foss CA; Havlinova B; Gresova M; Das G; Lisok A; Prada A; Barinkova M; Hubalek M; Pomper MG; Barinka C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932591
[TBL] [Abstract][Full Text] [Related]
3. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
4. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Wolf P; Freudenberg N; Bühler P; Alt K; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
Prostate; 2010 Apr; 70(5):562-9. PubMed ID: 19938014
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
7. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).
Tykvart J; Navrátil V; Sedlák F; Corey E; Colombatti M; Fracasso G; Koukolík F; Bařinka C; Sácha P; Konvalinka J
Prostate; 2014 Dec; 74(16):1674-90. PubMed ID: 25262926
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
[TBL] [Abstract][Full Text] [Related]
13. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
14. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.
Alt K; Wiehr S; Ehrlichmann W; Reischl G; Wolf P; Pichler BJ; Elsässer-Beile U; Bühler P
Prostate; 2010 Sep; 70(13):1413-21. PubMed ID: 20687214
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
[TBL] [Abstract][Full Text] [Related]
16. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
[TBL] [Abstract][Full Text] [Related]
17. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
18. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
19. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M
Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
